Trial Profile
A Double Blind, Randomized, Placebo Controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy on LDL-C of Evolocumab (AMG 145) in Subjects With HIV and With Hyperlipidemia and/or Mixed Dyslipidemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary)
- Indications Atherosclerosis; Dyslipidaemias; Hypercholesterolaemia; Hyperlipidaemia
- Focus Registrational; Therapeutic Use
- Acronyms BEIJERINCK
- Sponsors Amgen
- 12 Jan 2022 Results from open lable extension assessing long-term safety and efficacy of evolocumab in PWH, published in the AIDS
- 17 May 2021 Results assessing the evolocumab use in Patients with Human Immunodeficiency Virus and Dyslipidemia presented at the 70th Annual Scientific Session of the American College of Cardiology
- 11 May 2021 According to an Amgen media release, final results from the open-label extension period will be presented at the American College of Cardiology's 70th Annual Scientific Session & Expo (ACC.21).